Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 4 November 2022
- journal article
- review article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (12) , 1049-1064
Abstract
Background and Objective The incidence of cardiometabolic diseases is increasing because of an increase in the standard of living. Currently, clinical treatment strategies for cardiometabolic diseases mainly focus on maintaining glycemic and lipid profiles. The objective of this systematic review and meta-analysis was to evaluate the efficacy and safety of saroglitazar in patients with metabolic disease and provide evidence for clinical decision making. Methods We searched electronic databases (PubMed, Cochrane Central Register of Controlled Trials [CENTRAL], and Google Scholar) for randomized controlled trials that examined saroglitazar for the treatment of patients with cardiometabolic disease. A total of seven randomized controlled trials were included for the qualitative and quantitative synthesis. Mean difference (MD) and risk ratio with a 95% confidence interval (CI) were applied for continuous and dichotomous data, respectively. Results The overall effect of saroglitazar showed significant changes in triglycerides, total cholesterol, low-density lipoprotein, non-high-density lipoprotein, high-density lipoprotein, very low-density lipoprotein, alkaline phosphatase, and gamma-glutamyl transferase levels [MD: − 40.50; 95% CI − 58.09 to − 22.92; p < 0.00001; I2 = 78%], [MD: − 7.49; 95% CI − 11.33 to − 3.65; p = 0.0001; I2 = 41%], [MD: − 3.53; 95% CI − 6.91 to − 0.15; p = 0.04; I2 = 19%], [MD: − 8.08; 95% CI − 15.63 to − 0.54; p = 0.04; I2 = 58%], [MD: 2.04; 95% CI 0.17 to 3.92; p = 0.03; I2 = 69%], [MD: − 6.10; 95% CI − 9.40 to − 2.80; p = 0.0003; I2 = 65%], [MD: − 5.89; 95% CI − 7.50 to − 4.28; p < 0.00001; I2 = 98%], and [MD: − 1.64; 95% CI − 2.83 to − 0.45; p = 0.007; I2 = 95%], respectively. A subgroup analysis showed favorable outcomes with sarogiltazar 4 mg. There was a statistically non-significant reduced risk of adverse event occurrence in the saroglitazar treatment group. Conclusions Our study results conclude that the overall effect of saroglitazar was beneficial only in terms of lipid profiles and liver function parameters, whereas saroglitazar 4 mg showed a better therapeutic role in maintaining lipid and glycemic parameters in patients with cardiometabolic disease.Keywords
This publication has 41 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human SubjectsClinical Drug Investigation, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Targeting Residual Risk: The Rationale for the Use of Non-HDL CholesterolSouthern Medical Journal, 2010
- A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitusDiabetes & Vascular Disease Research, 2007
- Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin MonotherapyDiabetes Care, 2006
- Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ( / ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative studyDiabetes Care, 2006
- The Metabolic Syndrome in Asian Indians: Impact of Nutritional and Socio-economic Transition in IndiaMetabolic Syndrome and Related Disorders, 2004
- Asian Indians and Insulin Resistance Syndrome: Global PerspectiveMetabolic Syndrome and Related Disorders, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Diabetes and cardiovascular risk factors: the Framingham study.Circulation, 1979